ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) Russian patent published in 2018 - IPC C07D471/04 A61K31/4375 A61K31/4545 A61P3/10 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound represented by the following formula:

[Structural Formula 1]

or a pharmaceutically acceptable salt thereof. In Formula 1, ring P is pyridine; W is methylene; pyridine together with the adjacent ring forms a substituted tetrahydronaphthyridine; ring A is piperidine, azetidine or pyrrolidine; ring B is (1) a benzene ring optionally substituted with 1 to 4 substituents selected from a halogen atom, C_3-10 cycloalkyl group, C_1-6 alkoxy group and C_6-14 aryl group, optionally substituted with 1 to 3 halogen atoms, or (2) pyridine, indole or pyrazole, each optionally substituted with 1 to 3 substituents selected from C_1-6 alkyl group, C_3-10 cycloalkyl group, C_1-6 alkoxy groups and C_6-14 aryl group optionally substituted with 1 to 3 halogen atoms; R¹ represents a hydrogen atom or COOH; R² represents a hydrogen atom, C_1-6 alkyl group optionally substituted with C_1-6 alkoxy group, C_3-10 cycloalkyl group or COOH; and one of R¹ and R² is COOH, and each of R³, R⁴, R⁵ and R⁶ represents a hydrogen atom. Medicament, a method for the prevention or treatment of diabetes mellitus, a method for antagonising somatostatin receptor subtype 5, and the use of a compound of formula 1 are also disclosed.

EFFECT: present compound has the action of an SSTR5 antagonist and can be used as a medicament for the prevention or treatment of diabetes mellitus.

17 cl, 5 tbl, 89 ex